Highlights From the 2021 ASH Annual Meeting & Exposition
Posted: 12/21/2021 | By: Liz Janetschek Pasini

Question 1 of 5

Mosunetuzumab, which induced deep and durable remissions in patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy, is what kind of drug?

Choose 1